Asset profile
PLX-PAD
Cell therapy
Evidence outlook · program status
Discontinued, for reasons the sponsor has not stated
PLX-PAD is Pluri's allogeneic placenta-derived mesenchymal-stromal-cell product, developed through Phase 3 in critical limb ischaemia and intermittent claudication. Market-scoped: Pluri's FY2025 Form 10-K describes the peripheral artery disease work entirely in the past tense with all studies completed, and names knee osteoarthritis (the PROTO collaboration, approved by the Paul-Ehrlich-Institut in June 2025) as the only ongoing PLX-PAD development. The molecule and the company are both alive, so only the atherosclerotic-cardiovascular indication is recorded as stopped; the filing gives no reason or date. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.